Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
3.130
0.00 (0.00%)
Dec 26, 2025, 11:01 AM EST - Market open
Evotec SE Revenue
In the year 2024, Evotec SE had annual revenue of 796.97M EUR with 1.99% growth. Evotec SE had revenue of 163.89M in the quarter ending September 30, 2025, a decrease of -5.75%.
Revenue (ttm)
796.97M EUR
Revenue Growth
+22.68%
P/S Ratio
1.27
Revenue / Employee
168,136 EUR
Employees
4,740
Market Cap
1.13B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 133.41M | 21.59% |
| Dec 31, 2021 | 618.03M | 117.11M | 23.38% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | 446.44M | 71.03M | 18.92% |
| Dec 31, 2018 | 375.41M | 332.72M | 779.52% |
| Dec 31, 2009 | 42.68M | 3.07M | 7.75% |
| Dec 31, 2008 | 39.61M | 6.73M | 20.46% |
| Dec 31, 2007 | 32.89M | -7.69M | -18.95% |
| Dec 31, 2006 | 40.58M | -1.26M | -3.02% |
| Dec 31, 2005 | 41.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EVO News
- 18 days ago - Evotec: How Low A Company May Go While Still Being Attractive - Seeking Alpha
- 18 days ago - Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz - Accesswire
- 22 days ago - Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome - Accesswire
- 6 weeks ago - Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership - Accesswire
- 7 weeks ago - Evotec SE (EVO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities - Accesswire
- 7 weeks ago - In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties - Accesswire
- 2 months ago - Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025 - Accesswire